Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.

Hui Ming LinBrian Y LeeLesley CastilloCalan SpielmanJudith GroganNicole K YeungJames G KenchPhillip D StrickerAnne-Maree HaynesMargaret M CenteneraLisa M ButlerS Martin ShreeveLisa G HorvathRoger J Daly

Published in: The Prostate (2018)

Our findings suggest that co-administration of the FAK inhibitor, VS-6063, with docetaxel represents a potential therapeutic strategy to overcome docetaxel resistance in prostate cancer.

Keyphrases

prostate cancer
radical prostatectomy
locally advanced
cell migration
squamous cell carcinoma
radiation therapy